Brief: Abbisko Cayman Says CDE Approval Of Breakthrough Therapy Designation For Irpagratinib (Absk011)
26/05/2025 08:12
May 26 (Reuters) - Abbisko Cayman Ltd 2256.HK: CDE APPROVAL OF BREAKTHROUGH THERAPY DESIGNATION- FOR IRPAGRATINIB (ABSK011) OF ABBISKO THERAPEUTICS Further company coverage: 2256.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly